ELTX
Elicio Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Elicio Therapeutics has 6 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Elicio Therapeutics, Inc.
1.69
SentenceThe pending application directed to the mutant BRAF-driven cancer program is co-owned by Cornell University.
ELTX 10-Kaccession 0001601485-26-000027
SentenceWe also have an exclusive license from Dr. Roberto Chiarle for a patent family titled "Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination," which contains two granted U.S. patents.
ELTX 10-Kaccession 0001601485-26-000027
SentenceWe received funding for the initial development of ELI-007 through three grants from the Gastro-Intestinal ("GI") Research Foundation.
ELTX 10-Kaccession 0001601485-26-000027
SentenceOn January 27, 2016, we entered into an Exclusive Patent License Agreement with Massachusetts Institute of Technology ("MIT"), which has been amended from time to time (the "MIT License Agreement").
ELTX 10-Kaccession 0001601485-26-000027
SentenceIn September 2025, we announced an Investigator-Initiated Phase 1 Trial ("IIT") to be conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in PDAC.
ELTX 10-Kaccession 0001601485-26-000027
SentenceIn September 2025, we announced an Investigator-Initiated Phase 1 Trial ("IIT") to be conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in PDAC.
ELTX 10-Kaccession 0001601485-26-000027
Largest filed tie
—
—
—
Expected move
Inputsstraddle ±48.1%
spot 1.68exp Nov 20ATM strike 2.5ATM straddle 0.95IV 166%